Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2018

Open Access 01-12-2018 | Original investigation

Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus

Authors: R. Gimenes, C. Gimenes, C. M. Rosa, N. P. Xavier, D. H. S. Campos, A. A. H. Fernandes, M. D. M. Cezar, G. N. Guirado, L. U. Pagan, I. D. Chaer, D. C. Fernandes, F. R. Laurindo, A. C. Cicogna, M. P. Okoshi, K. Okoshi

Published in: Cardiovascular Diabetology | Issue 1/2018

Login to get access

Abstract

Background

Increased reactive oxygen species (ROS) generation in diabetes mellitus (DM) is an important mechanism leading to diabetic cardiomyopathy. Apocynin, a drug isolated from the herb Picrorhiza kurroa, is considered an antioxidant agent by inhibiting NADPH oxidase activity and improving ROS scavenging. This study analyzed the influence of apocynin on cardiac remodeling in diabetic rats.

Methods

Six-month-old male Wistar rats were assigned into 4 groups: control (CTL, n = 15), control + apocynin (CTL + APO, n = 20), diabetes (DM, n = 20), and diabetes + apocynin (DM + APO, n = 20). DM was induced by streptozotocin. Seven days later, apocynin (16 mg/kg/day) or vehicle was initiated and maintained for 8 weeks. Left ventricular (LV) histological sections were used to analyze interstitial collagen fraction. NADPH oxidase activity was evaluated in LV samples. Comparisons between groups were performed by ANOVA for a 2 × 2 factorial design followed by the Bonferroni post hoc test.

Results

Body weight (BW) was lower and glycemia higher in diabetic animals. Echocardiogram showed increased left atrial diameter, LV diastolic diameter, and LV mass indexed by BW in both diabetic groups; apocynin did not affect these indices. LV systolic function was impaired in DM groups and unchanged by apocynin. Isovolumic relaxation time was increased in DM groups; transmitral E/A ratio was higher in DM + APO compared to DM. Myocardial functional evaluation through papillary muscle preparations showed impaired contractile and relaxation function in both DM groups at baseline conditions. After positive inotropic stimulation, developed tension (DT) was lower in DM than CTL. In DM + APO, DT had values between those in DM and CTL + APO and did not significantly differ from either group. Myocardial interstitial collagen fraction was higher in DM than CTL and did not differ between DM + APO and CTL + APO. Serum activity of antioxidant enzymes glutathione peroxidase, superoxide dismutase (SOD), and catalase was lower in DM than CTL; apocynin restored catalase and SOD levels in DM + APO. Myocardial NADPH oxidase activity did not differ between groups.

Conclusion

Apocynin restores serum antioxidant enzyme activity despite unchanged myocardial NADPH oxidase activity in diabetic rats.
Literature
1.
Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–53.CrossRefPubMed
2.
American Diabetes Association. Standards of medical care in diabetes-2017. Abridged for primary care providers. Clin Diabetes. 2017;35:5–26.CrossRefPubMedCentral
3.
Holscher ME, Bode C, Bugger H. Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci. 2016;17:E2136.CrossRefPubMed
4.
Lorenzo-Almorós A, Tunón J, Orejas M, Cortés M, Egido J, Lorenzo Ó. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16:28.CrossRefPubMedPubMedCentral
5.
6.
Lew JK, Pearson JT, Schwenke DO, Katare R. Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol. 2017;16:10.CrossRefPubMedPubMedCentral
7.
Aydemir-Koksoy A, Bilginoglu A, Sariahmetoglu M, Schulz R, Turan B. Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress. J Nutr Biochem. 2010;21:827–33.CrossRefPubMed
8.
9.
Li JM, Gall NP, Grieve M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477–84.CrossRefPubMed
10.
Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. 2006;71:208–15.CrossRefPubMed
11.
Liu JJ, Lu Y, Ping NN, Li X, Lin YX, Li CF. Apocynin ameliorates pressure overload-induced cardiac remodeling by inhibiting oxidative stress and apoptosis. Physiol Res. 2017;66:741–52.PubMed
12.
Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003;42:206–12.CrossRefPubMed
13.
Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, Peng T. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes. 2009;58:2386–95.CrossRefPubMedPubMedCentral
14.
Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, Veeraveedu PT, Konishi T, Zhang S, Muslin AJ, Kodama M, Aizawa Y. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol. 2009;297:H911–9.CrossRefPubMed
15.
Li J, Shu H, Shen E, Wan L, Arnold JM, Peng T. Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress and reduces myocardial remodeling in type 1 diabetic mice. Diabetes. 2010;59:2033–42.CrossRefPubMedPubMedCentral
16.
Van den Worm E, Beukelman CJ, Van den Berg AJ, Kroes BH, Labadie RP, Van Dijk H. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur J Pharmacol. 2001;433:225–30.CrossRefPubMed
17.
Trevelin SC, Dos Santos CX, Ferreira RG, de Sá Lima L, Silva RL, Scavone C, Curi R, Alves-Filho JC, Cunha TM, Roxo-Júnior P, et al. Apocynin and Nox2 regulate NF-κB by modifying thioredoxin-1 redox-state. Sci Rep. 2016;6:34581.CrossRefPubMedPubMedCentral
18.
Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2015;23:406–27.CrossRefPubMedPubMedCentral
19.
Heumüller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schröder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 2008;51:211–7.CrossRefPubMed
20.
Rosa CM, Gimenes R, Campos DH, Guirado GN, Gimenes C, Fernandes AA, Cicogna AC, Queiroz RM, Falcão-Pires I, Miranda-Silva D, et al. Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus. Cardiovasc Diabetol. 2016;15:126.CrossRefPubMedPubMedCentral
21.
Liu ZH, Dai DP, Ding FH, Pan WQ, Fang YH, Zhang Q, Li M, Yang P, Wang XQ, Shen Y, et al. Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: aggravation of myocardial ischemic injury in rats by HMGB2 via ROS. Am J Physiol Heart Circ Physiol. 2017;312:H422–36.CrossRefPubMed
22.
Uysal A, Sahna E, Ozguler IM, Burma O, Ilhan N. Effects of apocynin, an NADPH oxidase inhibitor, on levels of ADMA, MPO, iNOS and TLR4 induced by myocardial ischemia reperfusion. Perfusion. 2015;30:472–7.CrossRefPubMed
23.
Gonzalez DR, Treuer AV, Lamirault G, Mayo V, Cao Y, Dulce RA, Hare JM. NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2014;307:H710–21.CrossRefPubMedPubMedCentral
24.
Zhang L, Li F, Zhi G, Zhang B, Chen YD. NADPH oxidase contributes to the left ventricular dysfunction induced by sinoaortic denervation in rats. Free Radic Res. 2015;49:57–66.CrossRefPubMed
25.
Qiu J, Zhao J, Li J, Liang X, Yang Y, Zhang Z, Zhang X, Fu H, Korantzopoulos P, Tse G, et al. Apocynin attenuates left ventricular remodeling in diabetic rabbits. Oncotarget. 2017;8:38482–90.PubMedPubMedCentral
26.
Gimenes C, Gimenes R, Rosa CM, Xavier NP, Campos DHS, Fernandes AAH, Cezar MDM, Guirado GN, Cicogna AC, Takamoto AHR, et al. Low intensity physical exercise attenuates cardiac remodeling and myocardial oxidative stress and dysfunction in diabetic rats. J Diabetes Res. 2015:ID 457848.
27.
Guimaraes JF, Muzio BP, Rosa CM, Nascimento AF, Sugizaki MM, Fernandes AA, Cicogna AC, Padovani CR, Okoshi MP, Okoshi K. Rutin administration attenuates myocardial dysfunction in diabetic rats. Cardiovasc Diabetol. 2015;14:90.CrossRefPubMedPubMedCentral
28.
Rosa CM, Xavier NP, Campos DH, Fernandes AA, Cezar MD, Martinez PF, Cicogna AC, Gimenes C, Gimenes R, Okoshi MP, et al. Diabetes mellitus activated fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats. Cardiovasc Diabetol. 2013;12:152.CrossRefPubMedPubMedCentral
29.
Lu J, Pontre B, Pickup S, Choong SY, Li M, Xu H, Gamble GD, Phillips AR, Cowan BR, Young AA, et al. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment. Cardiovasc Diabetol. 2013;12:28.CrossRefPubMedPubMedCentral
30.
Cezar MD, Damatto RL, Martinez PF, Lima AR, Campos DH, Rosa CM, Guizoni DM, Bonomo C, Cicogna AC, Gimenes R, et al. Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats. Cell Physiol Biochem. 2013;32:1275–87.CrossRefPubMed
31.
Martinez PF, Okoshi K, Zornoff LA, Carvalho RF, Oliveira Junior SA, Lima AR, Campos DH, Damatto RL, Nogueira CR, Dal Pai-Silva M, et al. Chronic heart failure-induced skeletal muscle atrophy, necrosis, and myogenic regulatory factors changes. Med Sci Monit. 2010;16:374–83.
32.
Martinez PF, Bonomo C, Guizoni DM, Junior SA, Damatto RL, Cezar MD, Lima AR, Pagan LU, Seiva FR, Bueno RT, et al. Modulation of MAPK and NF-kB signaling pathways by antioxidant therapy in skeletal muscle of heart failure rats. Cell Physiol Biochem. 2016;39:371–84.CrossRefPubMed
33.
Lima AR, Martinez PF, Damatto RL, Cezar MD, Guizoni DM, Bonomo C, Oliveira SAJ, Dal-Pai Silva M, Zornoff LA, Okoshi K, et al. Heart failure-induced diaphragm myopathy. Cell Physiol Biochem. 2014;34:333–45.CrossRefPubMed
34.
Oliveira Junior SA, Dal Pai-Silva M, Martinez PF, Lima-Leopoldo AP, Campos DH, Leopoldo AS, Okoshi MP, Okoshi K, Padovani CR, Cicogna AC. Diet-induced obesity causes metabolic, endocrine and cardiac alterations in spontaneously hypertensive rats. Med Sci Monit. 2010;16:BR367–73.PubMed
35.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and The European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–70.CrossRefPubMed
36.
Pagan LU, Damatto RL, Cezar MD, Lima AR, Bonomo C, Campos DH, Gomes MJ, Martinez PF, Oliveira SAJ, Gimenes R, et al. Long-term low intensity physical exercise attenuates heart failure development in aging spontaneously hypertensive rats. Cell Physiol Biochem. 2015;36:61–74.CrossRefPubMed
37.
Gomes MJ, Martinez PF, Campos DHS, Pagan LU, Bonomo C, Lima AR, Damatto RL, Cezar MD, Damatto FC, Rosa CM, et al. Beneficial effects of physical exercise on functional capacity and skeletal muscle oxidative stress in rats with aortic stenosis-induced heart failure. Oxid Med Cell Longev. 2016;2016:8695716.CrossRefPubMedPubMedCentral
38.
Okoshi K, Fioretto JR, Okoshi MP, Cicogna AC, Aragon FF, Matsubara LS, Matsubara BB. Food restriction induces in vivo ventricular dysfunction in spontaneously hypertensive rats without impairment of in vitro myocardial contractility. Braz J Med Biol Res. 2004;37:607–13.CrossRefPubMed
39.
Sugizaki MM, Carvalho RF, Aragon FF, Padovani CR, Okoshi K, Okoshi MP, Zanati SG, Pai-Silva MD, Novelli EL, Cicogna AC. Myocardial dysfunction induced by food restriction is related to morphological damage in normotensive middle-aged rats. J Biomed Sci. 2005;12:641–9.CrossRefPubMed
40.
Cicogna AC, Padovani CR, Okoshi K, Aragon FF, Okoshi MP. Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle. Am J Med Sci. 2000;320:244–8.CrossRefPubMed
41.
Okoshi MP, Cezar MD, Iyomasa RM, Silva MB, Costa LC, Martinez PF, Campos DH, Damatto RL, Minicucci MF, Cicogna AC, et al. Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. Int J Cardiol. 2016;222:569–75.CrossRefPubMed
42.
Cezar MD, Damatto RL, Pagan LU, Lima AR, Martinez PF, Bonomo C, Rosa CM, Campos DH, Cicogna AC, Gomes MJ, et al. Early spironolactone treatment attenuates heart failure development by improving myocardial function and reducing fibrosis in spontaneously hypertensive rats. Cell Physiol Biochem. 2015;36:1453–66.CrossRefPubMed
43.
Damatto RL, Martinez PF, Lima AR, Cezar MD, Campos DH, Oliveira SAJ, Guizoni DM, Bonomo C, Nakatani BT, Dal Pai Silva M, et al. Heart failure-induced skeletal myopathy in spontaneously hypertensive rats. Int J Cardiol. 2013;167:698–703.CrossRefPubMed
44.
Damatto RL, Lima AR, Martinez PF, Cezar MD, Okoshi K, Okoshi MP. Myocardial myostatin in spontaneously hypertensive rats with heart failure. Int J Cardiol. 2016;215:384–7.CrossRefPubMed
45.
Matsubara LS, Matsubara BB, Okoshi MP, Franco M, Cicogna AC. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol. 1997;75:1328–34.CrossRefPubMed
46.
Fernandes DC, Wosniak J, Pescatore LA, Bertoline MA, Liberman M, Laurindo FRM, Santos CXC. Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems. Am J Physiol Cell Physiol. 2007;292:C413–22.CrossRefPubMed
47.
Laurindo FRM, Fernandes DC, Santos CXC. Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. Methods Enzymol. 2008;441:237–60.CrossRefPubMed
48.
Oliveira-Junior SA, Martinez PF, Fan WYC, Nakatani BT, Pagan LU, Padovani CR, Cicogna AC, Okoshi MP, Okoshi K. Association between echocardiographic structural parameters and body weight in Wistar rats. Oncotarget. 2017;8:26100–5.CrossRefPubMedPubMedCentral
49.
Roe ND, Thomas DP, Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes Metab. 2011;13:465–73.CrossRefPubMed
50.
Shi XY, Hou FF, Niu HX, Wang GB, Xie D, Guo ZJ, Zhou ZM, Yang F, Tian JW, Zhang X. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology. 2008;149:1829–39.CrossRefPubMed
51.
Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005;67:1890.CrossRefPubMed
52.
Olukman M, Orhan CE, Celenk FG, Ulker S. Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions. J Diabetes Complicat. 2010;24:415–23.CrossRefPubMed
53.
Fernandes AA, Novelli EL, Okoshi K, Okoshi MP, Di Muzio BP, Guimaraes JF, Fernandes A Jr. Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomed Pharmacother. 2010;64:214–9.CrossRefPubMed
54.
Savi M, Bocchi L, Mena P, Dall’Asta M, Crozier A, Brighenti F, Stilli D, Del Rio D. In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2017;16:80.CrossRefPubMedPubMedCentral
55.
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.CrossRefPubMedPubMedCentral
56.
Cheng YS, Dai DZ, Dai Y, Zhu DD, Liu BC. Exogenous hydrogen sulphide ameliorates diabetic cardiomyopathy in rats by reversing disordered calcium-handling system in sarcoplasmic reticulum. J Pharm Pharmacol. 2016;68:379–88.CrossRefPubMed
57.
Brooks WW, Bing OHL, Boluyt MO, Malhotra A, Morgan JP, Satoh N, Colucci WS, Conrad CH. Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril. Hypertension. 2000;35:1203–9.CrossRefPubMed
58.
Prakoso D, De Blasio MJ, Qin C, Rosli S, Kiriazis H, Qian H, Du XJ, Weeks KL, Gregorevic P, McMullen JR, et al. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci. 2017;131:1345–60.CrossRefPubMed
59.
60.
Zheng H, Pu SY, Fan XF, Li XS, Zhang Y, Yuan J, Zhang YF, Yang JL. Treatment with angiotensin-(1-9) alleviates the cardiomyopathy in streptozotocin-induced diabetic rats. Biochem Pharmacol. 2015;95:38–45.CrossRefPubMed
61.
Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D, Takayanagi R. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis. 2015;240:250–9.CrossRefPubMed
62.
Radak Z, Chung HY, Goto S. Exercise and hormesis: oxidative stress-related adaptation for successful aging. Biogerontology. 2005;6:71–5.CrossRefPubMed
63.
Castor LR, Locatelli KA, Ximenes VF. Pro-oxidant activity of apocynin radical. Free Radic Biol Med. 2010;48:1636–43.CrossRefPubMed
64.
Riganti C, Costamagna C, Bosia A, Ghigo D. The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicol Appl Pharmacol. 2006;212:179–87.CrossRefPubMed
65.
Riganti C, Costamagna C, Doublier S, Miraglia E, Polimeni M, Bosia A, Ghigo D. The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol. 2008;228:277–85.CrossRefPubMed
66.
Li YQ, Li XB, Guo SJ, Chu SL, Gao PJ, Zhu DL, Niu WQ, Jia N. Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice. Acta Pharmacol Sin. 2013;34:352–9.CrossRefPubMedPubMedCentral
67.
Liu J, Zhou J, An W, Lin Y, Yang Y, Zang W. Apocynin attenuates pressure overload-induced cardiac hypertrophy in rats by reducing levels of reactive oxygen species. Can J Physiol Pharmacol. 2010;88:745–52.CrossRefPubMed
Metadata
Title
Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus
Authors
R. Gimenes
C. Gimenes
C. M. Rosa
N. P. Xavier
D. H. S. Campos
A. A. H. Fernandes
M. D. M. Cezar
G. N. Guirado
L. U. Pagan
I. D. Chaer
D. C. Fernandes
F. R. Laurindo
A. C. Cicogna
M. P. Okoshi
K. Okoshi
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2018
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0657-9

Other articles of this Issue 1/2018

Cardiovascular Diabetology 1/2018 Go to the issue

Correction

Correction to: Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up

Original investigation

Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes

Original investigation

Association of depression with evolution of heart failure in patients with type 2 diabetes mellitus

Original investigation

Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes

Original investigation

Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

Original investigation

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits